- Home
- TERN vs HUMA Comparison
TERN vs HUMA Comparison
Compare TERN & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- HUMA
- Stock Information
- Founded
- TERN 2017
- HUMA 2004
- Country
- TERN United States
- HUMA United States
- Employees
- TERN N/A
- HUMA N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- HUMA Health Care
- Exchange
- TERN Nasdaq
- HUMA Nasdaq
- Market Cap
- TERN 324.0M
- HUMA 367.6M
- IPO Year
- TERN 2021
- HUMA N/A
- Fundamental
- Price
- TERN $4.06
- HUMA $2.19
- Analyst Decision
- TERN Buy
- HUMA Strong Buy
- Analyst Count
- TERN 5
- HUMA 7
- Target Price
- TERN $15.63
- HUMA $13.00
- AVG Volume (30 Days)
- TERN 871.0K
- HUMA 3.7M
- Earning Date
- TERN 08-04-2025
- HUMA 08-12-2025
- Dividend Yield
- TERN N/A
- HUMA N/A
- EPS Growth
- TERN N/A
- HUMA N/A
- EPS
- TERN N/A
- HUMA N/A
- Revenue
- TERN N/A
- HUMA $517,000.00
- Revenue This Year
- TERN N/A
- HUMA N/A
- Revenue Next Year
- TERN N/A
- HUMA $896.45
- P/E Ratio
- TERN N/A
- HUMA N/A
- Revenue Growth
- TERN N/A
- HUMA N/A
- 52 Week Low
- TERN $1.87
- HUMA $1.15
- 52 Week High
- TERN $11.40
- HUMA $9.79
- Technical
- Relative Strength Index (RSI)
- TERN 64.02
- HUMA 43.83
- Support Level
- TERN $3.55
- HUMA $2.08
- Resistance Level
- TERN $4.30
- HUMA $2.30
- Average True Range (ATR)
- TERN 0.29
- HUMA 0.16
- MACD
- TERN -0.01
- HUMA -0.07
- Stochastic Oscillator
- TERN 71.13
- HUMA 12.94
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.